Drugs / CD68-ET3-LV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05265767 | Apr 2022 → Jun 2024 | hemophilia A | Christian Medical College, Vellore, India | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD68-ET3-LV | “Autologous HSCs were transduced with CD68-ET3-LV - a lentiviral vector including a new F8 transgene (ET3)” PMID 39655790 ↗ Dec 2024 |
| Action | Restore | “Gene therapy for hemophilia A with the use of lentiviral vector-transduced autologous HSCs resulted in stable factor VIII expression” PMID 39655790 ↗ Dec 2024 |
| Route | Intravenous | “administered by IV infusion” NCT05265767 ↗ |
| Target | F8 | “a new F8 transgene (ET3)” PMID 39655790 ↗ Dec 2024 |